<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical classification of pulmonary hypertension</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical classification of pulmonary hypertension</h1>
<div class="graphic"><div class="figure"><div class="ttl">Clinical classification of pulmonary hypertension</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single">Group 1 - Pulmonary arterial hypertension (PAH)</td> </tr> <tr> <td class="indent1">1.1 Idiopathic:</td> </tr> <tr> <td class="indent2">1.1.1 Non-responders at vasoreactivity testing</td> </tr> <tr> <td class="indent2">1.1.2 Acute responders at vasoreactivity testing</td> </tr> <tr> <td class="indent1">1.2 Heritable*</td> </tr> <tr> <td class="indent1">1.3 Associated with drugs and toxins*</td> </tr> <tr> <td class="indent1">1.4 Associated with:</td> </tr> <tr> <td class="indent2">1.4.1 Connective tissue disease</td> </tr> <tr> <td class="indent2">1.4.2 HIV infection</td> </tr> <tr> <td class="indent2">1.4.3 Portal hypertension</td> </tr> <tr> <td class="indent2">1.4.4 Congenital heart disease</td> </tr> <tr> <td class="indent2">1.4.5 Schistosomiasis</td> </tr> <tr> <td class="indent1">1.5 PAH with features of venous/capillary (PVOD/PCH) involvement</td> </tr> <tr> <td class="indent1">1.6 Persistent PH of the newborn</td> </tr> <tr> <td class="subtitle1_single">Group 2 - PH associated with left heart disease</td> </tr> <tr> <td class="indent1">2.1 Heart failure:</td> </tr> <tr> <td class="indent2">2.1.1 with preserved ejection fraction</td> </tr> <tr> <td class="indent2">2.1.2 with reduced or mildly reduced ejection fraction<sup>¶</sup></td> </tr> <tr> <td class="indent1">2.2 Valvular heart disease</td> </tr> <tr> <td class="indent1">2.3 Congenital/acquired cardiovascular conditions leading to post-capillary PH</td> </tr> <tr> <td class="subtitle1_single">Group 3 - PH associated with lung diseases and/or hypoxia</td> </tr> <tr> <td class="indent1">3.1 Obstructive lung disease or emphysema</td> </tr> <tr> <td class="indent1">3.2 Restrictive lung disease</td> </tr> <tr> <td class="indent1">3.3 Lung disease with mixed restrictive/obstructive pattern</td> </tr> <tr> <td class="indent1">3.4 Hypoventilation syndromes</td> </tr> <tr> <td class="indent1">3.5 Hypoxia without lung disease (eg, high altitude)</td> </tr> <tr> <td class="indent1">3.6 Developmental lung disorders</td> </tr> <tr> <td class="subtitle1_single">Group 4 - PH associated with pulmonary artery obstructions</td> </tr> <tr> <td class="indent1">4.1 Chronic thrombo-embolic PH</td> </tr> <tr> <td class="indent1">4.2 Other pulmonary artery obstructions<sup>Δ</sup></td> </tr> <tr> <td class="subtitle1_single">Group 5 - PH with unclear and/or multifactorial mechanisms</td> </tr> <tr> <td class="indent1">5.1 Haematological disorders<sup>◊</sup></td> </tr> <tr> <td class="indent1">5.2 Systemic disorders<sup>§</sup></td> </tr> <tr> <td class="indent1">5.3 Metabolic disorders<sup>¥</sup></td> </tr> <tr> <td class="indent1">5.4 Chronic renal failure with or without haemodialysis</td> </tr> <tr> <td class="indent1">5.5 Pulmonary tumour thrombotic microangiopathy</td> </tr> <tr> <td class="indent1">5.6 Fibrosing mediastinitis</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>PAH: pulmonary arterial hypertension; HIV: human immunodeficiency virus; PVOD: pulmonary veno-occlusive disease; PCH: pulmonary capillary haemangiomatosis; PH: pulmonary hypertension.</p>
<p>* Patients with heritable PAH or PAH associated with drugs and toxins might be acute responders.</p>
<p>¶ Left ventricular ejection fraction for heart failure with reduced ejection fraction: ≤40%; for heart failure with mildly reduced ejection fraction: 41 to 49%.</p>
<p>Δ Other causes of pulmonary artery obstructions include: sarcomas (high or intermediate grade or angiosarcoma), other malignant tumours (eg, renal carcinoma, uterine carcinoma, germ-cell tumours of the testis), non-malignant tumours (eg, uterine leiomyoma), arteritis without connective tissue disease, congenital pulmonary arterial stenoses, and hydatidosis.</p>
<p>◊ Including inherited and acquired chronic haemolytic anaemia and chronic myeloproliferative disorders.</p>
<p>§ Including sarcoidosis, pulmonary Langerhans's cell histiocytosis, and neurofibromatosis type 1.</p>
¥ Including glycogen storage diseases and Gaucher disease.</div><div class="graphic_reference">Reproduced with permission of the © European Society of Cardiology &amp; European Respiratory Society 2023: European Respiratory Journal 61 (1) 2200879; DOI: 10.1183/13993003.00879-2022. Published 6 January 2023.</div><div id="graphicVersion">Graphic 66348 Version 11.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
